|1.||WO||WO/2013/174874 - APPARATUS AND PROCESS FOR PROVIDING A COILED COLLAGEN CARRIER||28.11.2013||
|PCT/EP2013/060532||TAKEDA NYCOMED AS||BERTELSEN, Poul|
The present invention relates inter alia to an apparatus for providing a coiled collagen carrier. An apparatus according to the invention preferably comprises a device for applying moisture to a collagen carrier prior to coiling of the collagen carrier and a coiling device. The coiling device preferably comprises rotatable gripping means for gripping the collagen carrier along an edge and coiling the collagen carrier, and a support device supporting the collagen carrier while being coiled. In another aspect, the invention relates to a production facility wherein an apparatus according to invention is arranged.
|2.||WO||WO/2013/174879 - PACKAGING||28.11.2013||
|PCT/EP2013/060537||TAKEDA NYCOMED AS||BERTELSEN, Poul|
The present invention relates to a packaging for storing a form-stable coiled collagen carrier. The form-stable coiled collagen carrier comprises a collagen layer and a coating layer comprising thrombin and fibrinogen and having the shape of an elongated element with a number of windings of the collagen carrier about the longitudinal axis of the elongated element with at least one outer winding(s) being orientated so that the coating layer constitutes the outer surface of each of said outer winding(s). The packaging preferably comprises a container part having a compartment in which at least a part of the coiled collagen carrier is contained.
|3.||US||20130231374 - Novel Process For The Preparation Of Roflumilast||05.09.2013||
|13860264||KOHL Bernhard||KOHL Bernhard|
A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.
|4.||US||20130224299 - Novel Process For The Preparation Of Roflumilast||29.08.2013||
|13860248||KOHL Bernhard||KOHL Bernhard|
A method for the treatment of chronic obstructive pulmonary disease (COPD), including administering to a patient suffering from COPD, a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.
|5.||US||20130143849 - USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES||06.06.2013||
|13744962||NYCOMED GMBH||WURST Wilhelm|
Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children.
|6.||US||20130131123 - Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient||23.05.2013||
|13739457||DIETRICH Rango||DIETRICH Rango|
An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 μg of the roflumilast or salt thereof.
|7.||SG||188823 - PYRROLOPYRIMIDINECARBOXAMIDES||30.04.2013||
||2013014634||NYCOMED GMBH||STADLWIESER, JOSEF|
369 PYRROLOPYRIMIDINECARBOXAMIDES ABSTRACT The compounds of Formula (I) wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase. NO SUITABLE FIG.
|8.||IL||177073 - HYDROXY-6-HETEROARYLPHENANTHRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME||30.04.2013||
|9.||US||20130095146 - CICLESONIDE CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION||18.04.2013||
|13688659||NYCOMED GmbH||NAGANO Atsuhiro|
An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided.
|10.||US||20130096152 - NOVEL SALTS OF 6-HETEROCYCLE SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES||18.04.2013||
|13707969||NYCOMED GMBH||KAUTZ Ulrich|
Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions.